Real World Data

Intensive Diuretics Boost Fluid Loss, Kidney Injury in Heart Failure

Image
Intensive Diuretics Boost Fluid Loss, Kidney Injury in Heart Failure

United States – October 29, 2026 -- High-dose loop diuretics combined with adjuvant therapy produced an adjusted average weight loss of 4.6 pounds in heart failure inpatients, the largest of any strategy, but also came with higher rates of acute kidney injury, according to a study in the Journal of Cardiac Failure.

Study tracks 109,000 heart failure patients across US health systems

Researchers used Truveta Data to identify more than 109,000 patients hospitalized for heart failure between 2015 and 2022. Patients were grouped by the most intensive diuretic strategy used within the first 48 hours, ranging from low-dose loop diuretics alone to high-dose loop diuretics combined with thiazides or acetazolamide.

The team measured weight loss, hemoconcentration, in-hospital acute kidney injury, and the combined outcome of readmission or death within 90 days.

Truveta Data: 40% of Early Foundayo Users Had No Prior GLP-1 Use

Image
Truveta Data: 40% of Early Foundayo Users Had No Prior GLP-1 Use

United States – October 27, 2026 -- An analysis of 5,723 patients on Foundayo (oral orforglipron) found that 40.3% had no evidence of prior GLP-1 medication use, according to Truveta, which is pitching real-time "healthcare intelligence" to life science, healthcare and government teams.

Foundayo uptake runs mostly through primary care

Truveta researchers used Truveta Data to identify patients with a Foundayo prescription or medication dispense between April 1 and July 6, 2026. The drug was approved for obesity in April 2026.

General practice clinicians accounted for 60.0% of prescriptions, and advanced practice providers for another 31.9%. Only 0.1% of patients had evidence of recent oral semaglutide use.